Sabin Vaccine Institute

The Sabin Vaccine Institute ("Sabin") is a non-profit, 501(c)(3) organization dedicated to reducing needless human suffering from vaccine preventable and neglected tropical diseases through prevention and treatment. Sabin advocates for the control of infectious diseases such as HPV, pneumococcal disease, pertussis, rotavirus, rubella, and typhoid and neglected tropical diseases (NTDs) including human hookworm infection, ascariasis, trichuriasis, schistosomiasis, onchocerciasis, lymphatic filariasis (elephantiasis), and trachoma. The Sabin Vaccine Institute was founded in 1993 by Dr. H.R. Shepherd, Mrs. Heloisa Sabin, Dr. Robert M. Chanock, and Dr. Philip K. Russell and named in honor of one of medicine’s most pre-eminent scientific figures, Dr. Albert B. Sabin, best known for developing the oral live virus polio vaccine. The Institute continues Dr. Sabin’s vision by providing greater access to vaccines and essential treatments for hundreds of millions of people stuck in a cycle of pain, poverty and despair through its three main programs – Sabin Vaccine Development, the Global Network for Neglected Tropical Diseases, and Vaccine Advocacy and Education.


Some content from Wikipedia, licensed under CC BY-SA

Subscribe to rss feed

Diseases, Conditions, Syndromes

WHO recommends use of first typhoid conjugate vaccine

The World Health Organization (WHO) recommends the introduction of typhoid conjugate vaccine (TCV) for infants and children over six months of age in typhoid-endemic countries. This new policy will help ensure access to typhoid ...

Diseases, Conditions, Syndromes

Indonesia's competitiveness at risk from neglected diseases of poverty

February 27, 2014 – The control and elimination of neglected tropical diseases (NTDs) is one of the most cost-effective ways Indonesia can sustain economic growth and reduce inequality, said scientists today in an analysis ...

Diseases, Conditions, Syndromes

New study suggests potential shift in burden of pneumococcal disease

New studies revealed today by Latin American researchers and global health leaders suggest that the highest burden of deadly pneumococcal disease in Latin America may be shifting to adults as countries successfully immunize ...


Clinical trials for first-ever human hookworm vaccine advance

The Sabin Vaccine Institute (Sabin) today announced the start of Part II of its Phase I clinical trial of the Na-GST-1 vaccine candidate, marking another major milestone in the progress toward developing a human hookworm ...


Concerns over cost of dengue vaccine lessened with new study

Research funded by the Dengue Vaccine Initiative (DVI) involving an economic analysis of producing a tetravalent dengue vaccine shows that the cost could be as low as $0.20 per dose with an annual production level of 60 million ...